Chemical genetics can help decipher novel pathways underlying neurodevelopmental psychiatric impairments. Hoffman et al. (2016) utilized behavioral profiling of psychoactive compounds in zebrafish and identified estrogens as suppressors of a phenotype resulting from loss of an autism risk gene.
Modeling autism spectrum disorder (ASD) is extremely challenging, as this group of neurodevelopmental disorders manifests itself in a range of deficits including impaired social interaction, poor verbal and non-verbal communication, repetitive behaviors, and narrow interests (American Psychiatric Association, 2013) . A plethora of genes and chromosomal regions have been implicated in risk for ASD, and mouse model counterparts carrying mutations in such genes have been established (Aldinger et al., 2011) . Considering the phenotypic complexity and genotypic diversity of ASD within the human population, it is clear that mouse models with alterations in single or even several genes cannot recapitulate the entire ASD phenotype. However, as some of these mouse animal models do develop ''autistic-like'' neurodevelopmental and behavioral phenotypes, they may help us understand how ASD-associated genetic factors contribute to the human phenotype. Animal models that phenocopy one or more features of ASD can potentially be used for whole-organism-based screening for drugs that ameliorate the phenotype. Phenotypic suppressor molecules may affect a given phenotype by directly interacting with the targeted ASD-related factor and/or its pathway. Alternatively, these chemical suppressors may reveal a novel molecular pathway that indirectly modulates a disease-related phenotype. However, the time and resources required for highthroughput behavioral screens in mice are prohibitive.
Zebrafish provide a more amenable vertebrate animal model, exhibiting complex behaviors as early as the larval stages and offering a powerful wholeorganism platform for large-scale screening of small molecules that modulate behavior (Kokel et al., 2012) . In this issue of Neuron, Hoffman and colleagues employed a high-throughput behavioral platform in the zebrafish to identify pharmacological agents that suppress the phenotype caused by a loss of function of the ASD-linked contactin-associated protein-like 2 (CNTNAP2) gene (Hoffman et al., 2016) . CNTNAP2, a neuronal trans-membrane protein member of the neurexin superfamily, was originally described as a neuron-glia contact protein involved in clustering of voltagegated potassium channels in myelinated axons (Poliak et al., 1999 (Poliak et al., , 2003 . Humans bearing homozygous mutations in CNTNAP2 suffer from cortical dysplasia and focal epilepsy (CDFE) syndrome, and 70% of affected individuals display ASD characteristics including mental retardation, epileptic seizures, hyperactivity, and social deficits (Strauss et al., 2006) . A Cntnap2 knockout mouse reproduces key features of CDFE neuropathology and core autism-related deficits (Peñ agarikano et al., 2011). Functional conservation of CNTNAP2 has also been demonstrated in other species. For example, Cntnap2 expression is highly enriched in specific brain nuclei that regulate vocalization learning in the zebrafinch songbird, and in humans, sequence variations in CNTNAP2 gene are associated with impaired language acquisition (Panaitof et al., 2010; Whitehouse et al., 2011) .
In the present study, Hoffman et al. show that zebrafish cntnap2 mutant larvae display both developmental and behavioral impairments, some of which resemble the phenotypes reported in the mouse model for Cntnap2 deficiency (Hoffman et al., 2016) . These include global developmental reduction of forebrain GABAergic neurons, increased sensitivity to pentylenetetrazol-induced seizures, and nighttime hyperactivity. The authors undertook a unique approach to identify pharmacological effectors with relevance to autism-related deficits. Capitalizing on previous behavioral profiling of normal (wild-type) zebrafish larvae exposed to 550 known psychoactive compounds (Rihel et al., 2010) , they compared the effects of compounds in this behavioral dataset with the behavioral signature of the cntnap2 mutant. They then classified collections of compounds displaying either correlating or anti-correlating effects with respect to the cntnap2 mutant nighttime hyperactivity phenotype (Figure 1) .
They report that among the correlating collection, compounds that disrupt glutamatergic and GABAergic signaling recapitulate the behavioral profile of the mutant, consistent with its neuroanatomical phenotype. Interestingly, among compounds with anti-correlating effects, four of the top ten drugs have estrogenic activity. Several of these reversed specific behavioral phenotypes of the cntnap2 mutants. In particular, acute administration of the soybean-derived plant estrogen, biochanin A, and other estrogenic compounds specifically reversed nighttime hyperactivity of cntnap2 mutants (Figure 1 ). It should be emphasized that the estrogenic effect shown in the present study relies on the acute effectiveness of the drugs that should be verified by chronic treatment models.
How estrogens rescue the cntnap2 mutant behavioral phenotype remains to be resolved. That sex hormones could shape the structure of the developing nervous system and as a result alter adult animal behavior was suggested many years ago (Phoenix et al., 1959) . Moreover, the male predominance of ASD and the fact that ASD-like behaviors often correlate with a more masculine pattern imply that prenatal testosterone may be a contributing factor along with other genetic or environmental factors (Schaafsma and Pfaff, 2014) . It has been recently shown that Cntnap2-deficient mice display a decrease in the number of oxytocin neurons and acute administration of oxytocin improves the social deficits of Cntnap2 mutants (Peñ agarikano et al., 2015) . Estrogens were shown to affect oxytocin-dependent social recognition by controlling the expression of oxytocin and its receptor in the hypothalamus and amygdala, respectively (Choleris et al., 2003) . As the oxytocin neuronal system is evolutionarily conserved from nematodes to humans (Wircer et al., 2016) , it remains to be determined whether estrogenic compounds act through activation of oxytocin-mediated signaling to rescue the zebrafish cntnap2 mutant.
Taken together, Hoffman et al. demonstrate that combining quantitative behavioral profiling with in vivo chemical screening can be used to unravel new pharmacological interactions with an ASD risk gene. The study provides support to further investigate estrogenic compounds as potential suppressors of certain ASD phenotypes as well as a potential role for estrogen signaling pathways in development or expression of some ASD phenotypes. In addition, it validates the zebrafish model as a powerful tool to study the function of genes with relevance to ASD or other neurodevelopmental psychiatric disorders. (Hoffman et al., 2016) . (B) Quantitative behavioral profiling of wild-type zebrafish larvae treated with a collection of psychoactive compounds identifies small molecules that phenocopy the cntnap2 mutant phenotype (correlating) as well as compounds eliciting a behavioral signature opposite to that of mutant larvae (anti-correlating). This screen showed that molecules with estrogen-like activity suppress the cntnap2 mutant phenotype.
